DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Langerhans Cell Histiocytosis — screening already-approved drugs against its 46-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLangerhans Cell Histiocytosis maps to a 46-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for langerhans cell histiocytosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
isocitrate dehydrogenase (NADP(+)) 2 (IDH2) — IDH2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ndpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5I96 · 1.55 Å · ligand NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE (NDP). Experimental structure, not a prediction.
What the evidence adds up to
Langerhans cell histiocytosis is a rare disease whose clinical course ranges from spontaneous resolution to rapidly fatal multisystemic forms. Permanent consequences of the disease are more common than generally realised. A 2009 review noted that while clinical trials of standard chemotherapy agents continued, novel targeted therapy was considered likely to become feasible in the next decade.
By 2014, the detection of the BRAF V600E gain-of-function mutation in more than 50% of patients had been reported, alongside recognition of a lesional cytokine storm as a key determinant of disease progression. These findings substantiated new opportunities for targeted therapeutic approaches, though the fundamental events underlying pathogenesis remained elusive. A 2023 review of children with the disease summarised and analysed modern treatment approaches via targeted therapy, but provided no new trial data, response rates, or survival figures.
No abstract reports a completed trial of any targeted agent in Langerhans cell histiocytosis. The 2014 paper describes the BRAF V600E mutation as recurring in more than half of patients, yet no abstract gives the proportion of patients who actually received a BRAF inhibitor, nor any outcome from such treatment. The 2023 review analyses targeted therapy approaches but does not present concrete numbers for response or survival.
What is still missing are completed prospective trials with reported response rates and survival data for any targeted agent in this disease. Patient stratification by mutation status and risk group remains a work in progress. Funding for multicentre trials, rather than further reviews, is needed to determine whether the molecular insights of the past decade translate into measurable clinical benefit.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Disease in Childhood · 2009 · 83 citations
Langerhans cell histiocytosis
AbstractLangerhans cell histiocytosis is a rare disease. Depending on which organs are involved, the disease may prove rapidly fatal, develop a chronic reactivating but therapy-responsive pattern or resolve spontaneously. Understanding of the pathology of the disease is progressing rapidly, and while clinical trials of standard chemotherapy agents continue, it is likely that novel targeted therapy will become feasible in the next decade. Permanent consequences of the disease are more commoner than generally realised.
The Oncologist · 2014 · 54 citations · open access
New Insights Into the Molecular Pathogenesis of Langerhans Cell Histiocytosis
AbstractLangerhans cell histiocytosis (LCH) is a rare proliferative disorder characterized by an accumulation of cells sharing the major phenotypic features of cutaneous Langerhans cells. Given its variable clinical evolution, ranging from self-limiting lesions to multisystemic forms with a poor prognosis, in the last decades it has been debated whether LCH might not have a neoplastic rather than an inflammatory nature. However, although the fundamental events underlying the pathogenesis of LCH are still elusive, recent advances have strikingly improved our understanding of the disease. In particular, the identification of multiple interplays between LCH cells and their tumor microenvironment, along with the recognition of the lesional cytokine storm as a key determinant of LCH progression, has substantiated new opportunities for devising targeted therapeutic approaches. Strikingly, the detection of the rapidly accelerated fibrosarcoma isoform B(V600E) gain-of-function mutation as a genetic alteration recurring in more than 50% of patients has fueled the paradoxical picture of LCH as a tumor of the antigen-presenting cells that can evade rejection by the immune system. Thus, new evidence regarding the ontogeny of LCH cells, as well as a better understanding of the putative immune system frustrating strategy in LCH, may help to define the precise pathogenesis.
Postgraduate Medical Journal · 1997 · 51 citations · open access
Langerhans cell histiocytosis (histiocytosis X)
AbstractThere has been a renewed interest in Langerhans cell histiocytosis in recent years due both to advances in basic research and to improvements in diagnostic and treatment approaches. In this article, we review the various aspects of the disease and the potential implications of these recent scientific researches for our understanding and management of the disorder.
Вопросы современной педиатрии · 2023 · 3 citations · open access
Langerhans Cell Histiocytosis in Children: Literature Review
AbstractRelevant information on Langerhans cell histiocytosis development and course in children is presented. The current concepts of disease pathogenesis, principles of its severity evaluation, patients stratification into risk groups, as well as of clinical course features are described. Modern approaches to the disease treatment via targeted therapy are summarized and analyzed.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
